Perceptive Advisors LLC Buys 1,000,000 Shares of Immatics N.V. $IMTX

Perceptive Advisors LLC lifted its stake in Immatics N.V. (NASDAQ:IMTX) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,383,456 shares of the company’s stock after buying an additional 1,000,000 shares during the period. Immatics comprises 1.9% of Perceptive Advisors LLC’s portfolio, making the stock its 13th biggest holding. Perceptive Advisors LLC owned approximately 8.54% of Immatics worth $109,026,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares during the period. Quarry LP bought a new stake in shares of Immatics in the fourth quarter valued at about $84,000. Insigneo Advisory Services LLC bought a new stake in shares of Immatics in the third quarter valued at about $103,000. Fox Run Management L.L.C. bought a new stake in shares of Immatics in the fourth quarter valued at about $129,000. Finally, Graham Capital Management L.P. bought a new position in Immatics during the fourth quarter worth about $206,000. Institutional investors own 64.41% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of Immatics in a research note on Tuesday, May 19th. TD Cowen started coverage on shares of Immatics in a report on Tuesday, April 28th. They set a “buy” rating for the company. Jefferies Financial Group started coverage on shares of Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 price target for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Immatics in a report on Tuesday, June 9th. Finally, Mizuho set a $25.00 price target on shares of Immatics in a report on Thursday, February 19th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

Immatics Price Performance

Shares of Immatics stock opened at $9.52 on Thursday. The firm has a market cap of $1.28 billion, a P/E ratio of -4.78 and a beta of 1.30. The firm has a 50 day simple moving average of $10.72 and a 200 day simple moving average of $10.22. Immatics N.V. has a fifty-two week low of $5.05 and a fifty-two week high of $12.41.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. On average, sell-side analysts expect that Immatics N.V. will post -1.67 EPS for the current year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.